Literature DB >> 26182894

Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia.

Johannes Rentzsch1, Ada Stadtmann2, Christiane Montag3,4, Hagen Kunte3, Doris Plöckl3, Rainer Hellweg3, Jürgen Gallinat3, Golo Kronenberg3, Maria Christiane Jockers-Scherübl2.   

Abstract

Long-term cannabis use may confer cognitive deficits and increased risk of psychosis. However, the relationship between cannabis use and schizophrenia is complex. In particular, little is known about the effects of chronic cannabis use on the attention-related electric brain response in schizophrenia. We investigated auditory novelty and oddball P300 evoked potentials in a mixed sample of first-episode and chronic schizophrenic patients and healthy controls with (SZCA, n = 20; COCA, n = 20, abstinence ≥28 days) or without (SZ, n = 20; CO, n = 20) chronic cannabis use. Duration of regular cannabis use was 8.3 ± 5.6 (SZCA) and 9.1 ± 7.1 (COCA) years. In general, schizophrenic patients showed reduced P300 amplitudes. Cannabis use was associated with both a reduced early and late left-hemispheric novelty P300. There was a significant 'diagnosis × cannabis' interaction for the left-hemispheric late novelty P300 in that cannabis use was associated with a reduced amplitude in the otherwise healthy but not in the schizophrenic group compared with their relative control groups (corrected p < 0.02; p > 0.9, respectively). The left-hemispheric late novelty P300 in the otherwise healthy cannabis group correlated inversely with amount and duration of cannabis use (r = -0.50, p = 0.024; r = -0.57, p = 0.009, respectively). Our study confirms attentional deficits with chronic cannabis use. However, cannabis use may lead to different cognitive sequelae in patients with schizophrenia and in healthy controls, possibly reflecting preexisting alterations in the endocannabinoid system in schizophrenia.

Entities:  

Keywords:  Abstinence; Cognition; Marijuana; Novelty; P300; Schizophrenia

Mesh:

Year:  2015        PMID: 26182894     DOI: 10.1007/s00406-015-0616-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  84 in total

1.  Removing electroencephalographic artifacts by blind source separation.

Authors:  T P Jung; S Makeig; C Humphries; T W Lee; M J McKeown; V Iragui; T J Sejnowski
Journal:  Psychophysiology       Date:  2000-03       Impact factor: 4.016

2.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

3.  Delayed preattentional functioning in early psychosis patients with cannabis use.

Authors:  Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2012-03-09       Impact factor: 4.530

4.  Early and middle latency evoked potentials in medically and psychiatrically normal daily marihuana users: a paucity of significant findings.

Authors:  G Patrick; J J Straumanis; F A Struve; M J Fitz-Gerald; J E Manno
Journal:  Clin Electroencephalogr       Date:  1997-01

5.  Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.

Authors:  Susana de Sola; Thais Tarancón; Jordi Peña-Casanova; Josep María Espadaler; Klaus Langohr; Sandra Poudevida; Magí Farré; Antonio Verdejo-García; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

6.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

Review 7.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

8.  Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Authors:  Patrik Roser; Georg Juckel; Johannes Rentzsch; Thomas Nadulski; Jürgen Gallinat; Andreas M Stadelmann
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-10       Impact factor: 4.600

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Cannabis and motor function: fMRI changes following 28 days of discontinuation.

Authors:  Srinivasan S Pillay; Jadwiga Rogowska; Gen Kanayama; Staci Gruber; Norah Simpson; Harrison G Pope; Deborah A Yurgelun-Todd
Journal:  Exp Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.157

View more
  3 in total

Review 1.  Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.

Authors:  Rafael N Ruggiero; Matheus T Rossignoli; Jana B De Ross; Jaime E C Hallak; Joao P Leite; Lezio S Bueno-Junior
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

2.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

Review 3.  The Role of Gamma Oscillations in the Pathophysiology of Substance Use Disorders.

Authors:  Jessica U Ramlakhan; Ming Ma; Reza Zomorrodi; Daniel M Blumberger; Yoshihiro Noda; Mera S Barr
Journal:  J Pers Med       Date:  2020-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.